164 related articles for article (PubMed ID: 19641233)
1. HIV type-1 entry inhibitors with a new mode of action.
Fink RC; Roschek B; Alberte RS
Antivir Chem Chemother; 2009; 19(6):243-55. PubMed ID: 19641233
[TBL] [Abstract][Full Text] [Related]
2. A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: potential applications for preventing HIV-1 infection.
Yang J; Li L; Tan S; Jin H; Qiu J; Mao Q; Li R; Xia C; Jiang ZH; Jiang S; Liu S
Fitoterapia; 2012 Mar; 83(2):348-55. PubMed ID: 22155187
[TBL] [Abstract][Full Text] [Related]
3. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
[TBL] [Abstract][Full Text] [Related]
4. Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.
Bianchi E; Finotto M; Ingallinella P; Hrin R; Carella AV; Hou XS; Schleif WA; Miller MD; Geleziunas R; Pessi A
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12903-8. PubMed ID: 16129831
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
6. Old plants newly discovered: Cassia sieberiana D.C. and Cassia abbreviata Oliv. Oliv. root extracts inhibit in vitro HIV-1c replication in peripheral blood mononuclear cells (PBMCs) by different modes of action.
Leteane MM; Ngwenya BN; Muzila M; Namushe A; Mwinga J; Musonda R; Moyo S; Mengestu YB; Abegaz BM; Andrae-Marobela K
J Ethnopharmacol; 2012 May; 141(1):48-56. PubMed ID: 22326358
[TBL] [Abstract][Full Text] [Related]
7. A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro.
Chang CH; Hinkula J; Loo M; Falkeborn T; Li R; Cardillo TM; Rossi EA; Goldenberg DM; Wahren B
PLoS One; 2012; 7(7):e41235. PubMed ID: 22844444
[TBL] [Abstract][Full Text] [Related]
8. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
Hamza A; Zhan CG
J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
[TBL] [Abstract][Full Text] [Related]
9. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion.
Nagashima KA; Thompson DA; Rosenfield SI; Maddon PJ; Dragic T; Olson WC
J Infect Dis; 2001 Apr; 183(7):1121-5. PubMed ID: 11237840
[TBL] [Abstract][Full Text] [Related]
11. HIV entry inhibitors: progress in development and application.
Lai WH; Huang L; Chen CH
Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
[TBL] [Abstract][Full Text] [Related]
12. HIV entry inhibitors: a new generation of antiretroviral drugs.
Krambovitis E; Porichis F; Spandidos DA
Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
[TBL] [Abstract][Full Text] [Related]
13. Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
Liu S; Lu H; Zhao Q; He Y; Niu J; Debnath AK; Wu S; Jiang S
Biochim Biophys Acta; 2005 May; 1723(1-3):270-81. PubMed ID: 15823507
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide.
Harman S; Herrera C; Armanasco N; Nuttall J; Shattock RJ
Antimicrob Agents Chemother; 2012 May; 56(5):2347-56. PubMed ID: 22330930
[TBL] [Abstract][Full Text] [Related]
15. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
16. Selection of gp41-mediated HIV-1 cell entry inhibitors from biased combinatorial libraries of non-natural binding elements.
Ferrer M; Kapoor TM; Strassmaier T; Weissenhorn W; Skehel JJ; Oprian D; Schreiber SL; Wiley DC; Harrison SC
Nat Struct Biol; 1999 Oct; 6(10):953-60. PubMed ID: 10504731
[TBL] [Abstract][Full Text] [Related]
17. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
18. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors.
Rusert P; Kuster H; Joos B; Misselwitz B; Gujer C; Leemann C; Fischer M; Stiegler G; Katinger H; Olson WC; Weber R; Aceto L; Günthard HF; Trkola A
J Virol; 2005 Jul; 79(13):8454-69. PubMed ID: 15956589
[TBL] [Abstract][Full Text] [Related]
19. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.
Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K
Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803
[TBL] [Abstract][Full Text] [Related]
20. Resistance to HIV-1 entry inhibitors.
Olson WC; Maddon PJ
Curr Drug Targets Infect Disord; 2003 Dec; 3(4):283-94. PubMed ID: 14754430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
